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Approximately one-third of individuals with epilepsy do not respond to antiepileptic medications, and many patients with medically intractable epilepsy ultimately undergo surgical resection of a seizure focus. 2, 3 Intractable focal epilepsy poses a particular challenge when preoperative brain magnetic resonance imaging (MRI) does not reveal a seizure-related structural abnormality, referred to conventionally as "nonlesional focal epilepsy" (NLFE). Although germline genetic variants in a small number of genes-including KCNT1, LGI1, RELN, NPRL2, NPRL3, GRIN2A, and DEPDC5-have been associated with familial and sporadic focal epilepsy, [4] [5] [6] [7] [8] [9] [10] [11] [12] the genetic basis for the majority of focal epilepsies remains unknown. A number of human epilepsy syndromes associated with early onset seizures and intellectual disability have been associated with de novo variants in genes involved in early brain development and epileptogenesis. 10, [13] [14] [15] [16] [17] Recent studies have also identified brain-specific somatic variants in focal epilepsy due to malformations of cortical development (MCD), including hemimegalencephaly and the more common, radiographically evident focal cortical dysplasia (FCD) type II, [18] [19] [20] [21] characterized pathologically by the presence of dysmorphic neurons. 22 These variants arise in the postzygotic state, creating a mosaic of variant-carrying cells intermixed with variantnegative cells. Pathological evaluation of surgical epilepsy specimens often reveals FCD, even in cases in which a malformation was not evident on preoperative neuroimaging. 23 In part on the basis of these observations, it has been suspected that focal epilepsy in patients without clear radiographic malformation to which seizures can be attributed may also be caused by somatic variants in focal regions of the brain, resulting in localized network disruption. 24, 25 We hypothesized that somatic mutation, likely during corticogenesis, results in variants that would be detectable in brain tissue resected during epilepsy surgery, even in patients without explanatory lesions detected with modern neuroimaging. To test this hypothesis, we analyzed data from exome sequencing and targeted deep sequencing of a broad list of epilepsy-and malformationrelated genes of paired DNA from resected brain and leukocytes in 18 individuals with NLFE. We identified low-level somatic variants in SLC35A2 only in brain from 3 of 18 individuals with NLFE (17%), 2 of whom had pathological findings consistent with FCD type Ia, defined by disordered cortical lamination without dysmorphic neurons. 22 Through additional investigation of an MCD-related epilepsy cohort (n 5 38), we identified 2 additional cases harboring somatic SLC35A2 variants in brain, each with focal epilepsy and radiographic lesions suggestive of FCD. We thus provide compelling evidence for an association of somatic variants in SLC35A2 with intractable focal epilepsy, both with and without radiographic evidence of a seizure-associated lesion on neuroimaging.
Subjects and Methods

Participants
For all cases included in research and sequenced, clinical determination of localization of the epileptogenic region and candidacy for focal resection was determined by standard clinical practice at each site, incorporating seizure semiology, electroencephalographic (EEG) data, structural MRI, functional imaging (positron emission tomography, single photon emission computed tomography), and consensus at epilepsy surgery conferences.
At each center, review of clinical data was performed by that center's research team, with input from involved clinicians, to identify eligible participants prior to enrollment. To be eligible for the study enrolling patients with NLFE, it was required ANNALS of Neurology that the participant had no lesion identified on MRI that was felt to be responsible for seizures and that the patient had a planned or completed surgical resection. Focal features on other modalities, such as nuclear imaging studies, were not considered criteria for exclusion. Eighteen individuals with NLFE undergoing focal resection as treatment for intractable epilepsy were enrolled from Columbia University Medical Center, New York University Langone Medical Center, and University of California, San Francisco (Supplementary Table S1 ). To be eligible for the study enrolling patients with MCD, it was required that the patient have MRI findings consistent with FCD, polymicrogyria, or hemimegalencephaly and have a planned or completed surgical resection. Thirty-eight individuals with intractable epilepsy and MCD were enrolled from Boston Children's Hospital, Duke University Medical Center, and Lucille Packard Children's Hospital at Stanford (Supplementary Table S1 ). All patients provided consent for research approved by the respective institutional review boards.
For cases described in detail here with somatic variants identified in SLC35A2, epilepsy and general medical history, neuroimaging, and neuropathological data were reviewed in detail by a team of board-certified physicians, including epileptologists (M.R.W., P.B.C., A.H.P.), a neuroradiologist (E.Y.), and neuropathologists (D.Z., H.G.W.L., PDC) in addition to the referring neurologists and neurosurgeons for each case. Seizure semiology and postoperative Engel outcome scores were characterized according to International League against Epilepsy (ILAE) terminology. 26 Neuropathological analysis assessed specimens for features of FCD based on established ILAE criteria.
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Next Generation Sequencing
We extracted DNA from 1 regions of resected brain specimens and from leukocytes from the same individuals using a DNeasy Blood & Tissue Kit (Qiagen, Valencia, CA). Highdepth exome sequencing was performed for all 18 cases with NLFE as well as the 38 cases with MCDs using a NimbleGen Systems (Madison, WI) SeqCap EZ V3.0 Exome Enrichment Kit using established methods. 14 To increase sensitivity to detect variants present at low allele frequency, we performed ultrahigh-depth targeted sequencing of 2.5 megabases (Mb) of genomic sequence encompassing 838 genes (Supplementary Table  S2 ), including 274 genes related to the PI3K-AKT-mTOR pathway, 308 genes implicated in neurogenesis, and a subset of epilepsy-associated genes that included SLC35A2, with the remaining genes included for other genetic studies unrelated to this work (SeqCap EZ; Roche, Basel, Switzerland). Targeted  sequencing was performed on 17 of 18 NLFE samples and 30  of 38 MCD samples (Supplementary Table S1 ). Alignment and variant calling were performed using established methods. 14 
Somatic Variant Calling
Somatic single nucleotide variants (sSNVs) and somatic insertion-deletion variants (sindels) were called from aligned BAM files using Mutect2 in all cases and controls. 27 In addition to sSNVs and sindels passing recommended filters, we included short tandem repeat variants that failed the Mutect2 
Test for Enrichment of Somatic Variants in Individual Genes
To ensure we had the sensitivity to detect somatic variants present at low allele frequency, we limited these analyses to the protein coding regions (defined by Consensus Coding Sequence version 14) and the 2-base pair highly conserved splice sites flanking exons included on the ultra-high-depth targeted sequencing gene panel. Among the qualifying calls, we observed a high rate of G-T substitutions (84% of single nucleotide substitutions), which are a well-recognized Illumina sequencing error and can also arise from oxidative DNA damage. 28, 29 This overrepresentation was less pronounced in variants with higher VAF (>2%) for variants called in the targeted sequencing data (69%) compared to those with a VAF between 1 and 2% (88%). To address this artifact, we restricted enrichment analyses to somatic calls with VAF 2%. We then compiled all qualifying variants calls (defined above) in these regions with VAF 2%. Assuming no sequencing error and that each allele is equally likely to be sequenced, when the variant site was sequenced to at least 150-fold and the true frequency was at least 2%, we have a 95% chance of calling at least 1 variant allele. We therefore calculated the "callable real estate" across the 2.5Mb of genomic sequence for each individual sequenced to 150-fold in both brain and leukocyte DNA. We then calculated the individual's mutability across each gene on the custom capture sufficiently sequenced in that individual by summing the trinucleotide mutability for each possible single base substitution across the callable real estate.
Using these data, we tested for enrichment of somatic calls in individual genes using a previously published method. 30 In brief, we compared the observed number of somatic variants within each gene to a null rate in which somatic variants are randomly placed within the individual's callable real estate in accordance with the sequence-context-dependent mutation rate. We randomly distributed the somatic calls in this way 1,000,000 times to establish the null. This observed versus expected contrast was calculated for each individual, thereby explicitly accounting for interindividual differences in number of variants that may arise from other sources (eg, environmental exposure, DNA quality). To calculate the gene-level p value, we computed the proportion of simulated statistics that are as extreme or more extreme than that computed from the observed somatic variants.
Variant Confirmation
Somatic variants in SLC35A2 were confirmed to be present in DNA derived from the brain tissue and absent in DNA from leukocytes using digital droplet polymerase chain reaction (ddPCR; QX-200 Droplet Digital PCR system; Bio-Rad Laboratories, Hercules, CA) or conventional PCR (Sanger sequencing), depending on the level and type of variant.
Control Cohorts
Variant frequencies were evaluated in a control dataset of 13,472 individuals sequenced from genetic studies at the Columbia Institute for Genomic Medicine. Approximately 6,900 were neuropsychiatrically normal, and the remaining individuals had conditions without known comorbidities with epilepsy or MCD. We also used control data available in ExAC and gnomAD 31 to ascertain population allele frequencies in the germline.
To evaluate the frequency of somatic variants in SLC35A2 in brain, we evaluated paired next generation sequencing data (from the high-depth targeted sequencing panel) from DNA from 20 autopsy-collected cortical brain specimens and matched leukocyte-derived DNA collected premortem from individuals with Alzheimer disease or dementia from the New York Brain Bank at Columbia University.
Phosphorylated Ribosomal S6 Immunohistochemistry
Representative fixed sections of each from the 5 cases and agematched postmortem neocortical fixed sections were probed with antibodies recognizing phosphorylated ribosomal S6 protein (P-S6; Ser 240/244, mouse monoclonal; Cell Signaling Technology, Danvers, MA; 1:250) to assess the extent of mTOR signaling and NeuN (1:100, mouse monoclonal; Novus Biologicals, Littleton, CO).
Results
Identification of Somatic Variants in SLC35A2 Present in Brain
We first collated all qualifying somatic variants (Subjects and Methods) from exome sequencing and targeted deep sequencing of 838 genes (see Supplementary Table S2 ) of paired DNA from resected brain and leukocytes in the 18 individuals with NLFE and 38 with MCD (Supplementary Table S1 ). Exome and targeted sequenced DNA pairs were sequenced across protein-coding regions to an average depth of 137-fold 6 41 and 492-fold 6 121, respectively, with an average of 12 and 4 qualifying somatic variants called from exome and targeted sequencing, respectively (see Supplementary Table S1 ). We observed variants in SLC35A2, which is located on the X chromosome, present in brain and absent in leukocytes, in 3 of 18 cases with NLFE (Table 1) . These variants are present only in a subset of cells, consistent with having been acquired in the postzygotic state. The brain specimen from Case 1 (female) harbored the variant Ser304Pro predicted to be protein-altering (PolyPhen-2, probably damaging; Sorting Intolerant from Tolerant [SIFT], deleterious; Combined Annotation Dependent Depletion [CADD], 26.7) with VAF of 3.3% and 6.5%, from exome and targeted sequencing. This indicates that between 6.6 and 13% of brain cells in the tested specimens have the variant because the patient is female (XX) and for each cell with the variant we would expect there to be 1 variant allele and 1 reference allele (heterozygous genotype). We were able to obtain DNA from a buccal swab from Case 1, from which no variant alleles were detected using ddPCR, suggesting that the mutation occurred after neuroectoderm formation. Case 2 (male) harbored an in-frame indel (codon duplication) Leu113dup in brain tissue, and Case 3 (male) a frameshift indel (codon duplication) a frameshift indel Ser212Leufs*9. VAFs from exome and target sequencing ranged between 2 and 14%, respectively. Because these were both male (XY) patients, we estimate that between 2 and 14% of cells in the assayed brain tissue specimens carry the variant (hemizygous genotype; see Table 1 ). Despite nonlesional MRIs, Cases 2 and 3 had pathological evidence of FCD type I (Table 2) . From 38 individuals with MCDs, we identified somatic variants in SLC35A2 in brain tissue from 2 male individuals, both with FCD suggested by MRI (see Table  2 ). Case 4 harbored the putatively damaging missense variant Arg55Leu (PolyPhen-2, probably damaging; SIFT, deleterious; CADD, 34), and Case 5 the frameshift indel Ala253Glyfs*100. The VAFs for these cases ranged from 19 to 53%, reflecting 19 to 53% of cells carrying the variant (see Table 1 ).
Confirmation of Somatic Variants in Cases and Absence in Controls
The 4 somatic variants observed in Cases 1 to 4 were confirmed with ddPCR, and the variant for Case 5 (Ala253Glyfs*100) with Sanger sequencing. The percentage of variant alleles estimated using ddPCR highly correlated with that detected with next generation sequencing results above (see Table 1 ). Comparing the VAF across all available specimens per case, we observed highly variable levels within cases (Fig 1) . All 5 variants are absent from local control cohorts and public variant databases (listed in Subjects and Methods). In 20 control brains sequenced to the same depth (or more) on average as cases and subjected to identical calling algorithms, no somatic variants in SLC35A2 were found (see Supplementary Table S3 ).
We next assessed whether the somatic variants observed were selectively enriched in SLC35A2 across individuals with nonlesional and lesional epilepsy using a published method. 30 The uncorrected p value associated with observing 4 qualifying variants in SLC35A2 in a cohort of 56 individuals, using the criteria described above in Subjects and Methods, was <1 3 10 26 . The fifth somatic variant in SLC35A2 did not reside in the callable real estate, because the site was only covered 133-fold (see Table 1 ), not meeting the minimum coverage requirement of 150-fold in the targeted sequence data. Correcting for the 838 protein-coding genes sequenced on the targeted sequencing panel using a Bonferroni correction, SLC35A2 is significantly enriched for somatic variants. No other gene was significantly enriched for somatic variants.
Clinical, Neuroimaging, and Neuropathological Features of the Mosaic SLC35A2 Cases
Although all 5 patients harboring mosaic variants in SLC35A2 had intractable epilepsy leading to surgical resection, they represent a wide phenotypic range (see Table 2 ). In keeping with the brain-localized presence of the SLC35A2 variants, no patients were reported to have any symptoms or signs classically associated with a glycosylation defect, such as inverted nipples or cerebellar atrophy.
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All 3 cases with NLFE presented with focal epilepsy in childhood or adolescence and brain MRI without overt structural abnormality identified as responsible for their epilepsy. Case 1 is a young woman with onset of focal intractable epilepsy at 13 years, normal intelligence, and a normal neurological examination. MRI was FIGURE 1: Variant allele frequency (VAF) across all available specimens as detected with digital droplet polymerase chain reaction (Cases 1, 2, 3, and 5) or next generation sequencing (Case 4). Data are presented as mean 6 standard deviation. Case 1 (2 separate surgeries): 2 specimens (1 and 2) were collected from a right frontal resection within the supplementary motor area, and 5 specimens (3, 4, 5, 6, and 7) were collected from the right frontal premotor region anterior to the precentral sulcus. Case 2: 2 specimens were collected from a parietal precuneate and posterior two-thirds cingulate resection. Case 3: 2 specimens were collected from a right posterior temporal-occipital resection. Case 4: a temporal lobe specimen was collected as part of a functional hemispherectomy. Case 5: a frontal lobe specimen was collected as part of a right frontal resection. 
(K, O), and Case 5 (D, H, L, P). Axial T2 (A-D, K) and coronal T2 (E-H, L) images
demonstrated grossly normal cerebral volume and preserved size of the hippocampi in all 5 subjects, allowing for some minimal prominence of the lateral ventricles and variant underrotation of the left hippocampus in Case 1 (E). For Case 1, Case 2, and Case 3, there was no evidence of a malformation of cortical malformation apart from a tiny probable right frontal periventricular gray matter heterotopion in Case 1 (arrows in axial and sagittal T1-weighted images, I and M). For Cases 1, 2, and 3 there was also no evidence of a significant parenchymal injury or a metabolic/neurodegenerative condition, apart from nonspecific findings that were not thought to be related to seizure: an incidental left caudothalamic groove germinolytic cyst in Case 1 (asterisk in A), punctate mineralization versus hemosiderin deposition in the left temporoparietal cortex of Case 2 (arrow in susceptibility-weighted imaging, J), and some minimal cerebellar vermis volume loss in Case 3 (arrow in sagittal T1 series, N). By comparison, Case 4 and Case 5 demonstrated moderate to extensive parenchymal signal abnormality. In Case 4, T2-weighted imaging demonstrated diffuse haziness of the cerebral white matter concentrated in the right-greater-than-left frontotemporal lobes and right forceps minor (outlined by arrowheads in axial and coronal T2-weighted sequences, K and O). This pattern was consistent with cortical dysplasia and brain dysmyelination/gliosis; cortical dysplasia was thought unlikely to solely explain the findings given the extent of signal abnormality, and tumor was thought unlikely given the lack of mass effect. Whereas T1-and T2-weighted imaging appeared grossly normal for Case 5, volumetric fluid-attenuated inversion recovery (FLAIR) imaging demonstrated loss of gray-white matter differentiation throughout the lower half of the right frontal lobe (arrowheads in coronal volumetric FLAIR, P; corresponding image slice on coronal T2, L). Although lacking a transmantle sign specific for cortical dysplasia, the regional blurring of gray-white matter differentiation in Case 5 was most suggestive of a focal cortical dysplasia; however, regional dysmyelination/gliosis could conceivably also have this appearance.
interpreted clinically as not having a structural abnormality that explained the focal epilepsy; a small periventricular signal abnormality (Fig 2) was identified during post hoc review. Epilepsy surgery at age 17 years resulted in seizure freedom for 7 to 8 months, but seizures recurred, necessitating a second resection in the same area, performed at age 18 years. She has remained seizure-free since her second surgery. Histopathological examination of resected brain tissue from the first surgery revealed patchy gliosis but no architectural abnormalities, whereas tissue from the second surgery showed Chaslin marginal sclerosis (and subacute infarcts in the setting of electrode placement; see Table 2 , Fig 3) . Case 2 is a boy who had mild language delay and onset of focal seizures with impaired awareness and secondarily generalized seizures at age 2 years. He had a right homonymous quadrantanopia on preoperative ophthalmological examination, contralateral to the EEG seizure focus. MRI did not reveal a lesion to explain the focal epilepsy or visual field defect. Focal resection of an electrographically defined seizure focus, limited by the presence of adjacent eloquent cortex, did not result in sustained seizure control. Pathology of surgically resected brain revealed FCD type Ia, Chaslin marginal sclerosis, and mild patchy microgliosis. Case 3 is a young man who developed intractable epilepsy with focal seizures with impaired awareness beginning at age 17 years, normal intelligence, and a normal neurological examination. Pathology in Case 2 and Case 3 demonstrated findings consistent with FCD type Ia (see Table 2 , Fig 3) .
Both SLC35A2 variant-carrying cases from the MCD cohort had intractable epilepsy with localization consistent with a visible lesion suspected to be FCD based on MRI. Case 4 is a boy who presented with infantile spasms at 4 months and severe intellectual disability. MRI showed a right frontotemporal lesion suspicious for FCD versus gliosis and bilateral white matter abnormalities (see Fig 2) . He continues with intractable epilepsy after functional hemispherectomy. Case 5 is a boy who had onset of epileptic spasms at age 14 months and mild developmental delay, with mild intellectual disability diagnosed on assessment at age 7 years. His MRI revealed a lesion consistent with FCD, and there was good concordance between EEG and MRI preoperatively; he remains seizure-free 2 years after focal resection. Both cases, despite preoperative MRI suggestion of MCD, showed only gliosis on neuropathological review; for Case 4, available tissue was limited, as the therapeutic procedure was primarily a disconnection rather than a resection. Both had a mild excess of neurons in the white matter and a few scattered SMI31-positive neurons but did not have evidence for FCD based on ILAE criteria. 22 The presence of MRI appearance or pathological evidence of FCD in Cases 2 to 5 prompted assessment of increased mTOR activation, because classically FCDs have been associated with mTOR-related genetic abnormalities. 11, 21, [33] [34] [35] [36] [37] [38] [39] [40] [41] [42] Consistent with previous reports, we found low levels of baseline P-S6 immunoreactivity in control brain sections within scattered cortical neurons across all layers in the subpial region of layer I (Fig  4) . 43, 44 A similarly low level of baseline P-S6 labeling was observed in the SLC35A2-associated cases (see Fig  4) , suggesting that SLC35A2 haploinsufficiency does not result in activation of mTOR signaling.
Discussion
By sequencing brain specimens from 56 individuals undergoing epilepsy surgery for intractable neocortical epilepsy with and without MCD on MRI, we identified 5 individuals with mosaic variants in SLC35A2 that are predicted to be deleterious. Variants in SLC35A2 were not present in DNA from leukocytes from the same individuals, confirming somatic (postzygotic) rather than germline origin of the variants, consistent with the lack of other clinical features suggesting a more generalized disorder of glycosylation in these cases. SLC35A2 is the only gene for which we observed more somatic variants than we would expect to observe in a single gene by chance, supporting the assertion that somatic SLC35A2 variants are associated with intractable focal epilepsy. Nonsynonymous germline variants in SLC35A2 are uncommon in the population, indicating that such variants are under strong negative selection and likely to result in a severe phenotype. Specifically, there are no loss-of-function variants in the canonical transcript of SLC35A2 reported in the > 130,000 individuals in the gnomAD database, and likewise only 6 PolyPhen-2 probably damaging missense alleles are reported in this population (Fig 5) . SLC35A2, located at Xp11.23, encodes a UDPgalactose transporter, a member of the nucleotide-sugar transporter family that transports galactose from the cytosol or nucleus into Golgi vesicles. The encoded protein is a multipass membrane protein that permits transport of galactose necessary for glycosylation. The first evidence for a role for SLC35A2 in disease came from a report of 2 male patients with mosaic variants and 1 female patient with a de novo germline variant in SLC35A2, all with apparent glycosylation disorders. 45 Based on these findings, SLC35A2 was included as a cause of type IIm congenital disorders of glycosylation, multisystem disorders associated with seizures. Subsequently, germline heterozygous putative loss-of-function de novo variants, including missense, nonsense, and frameshift indels, in SLC35A2 have been identified in multiple girls with epileptic encephalopathy (see Fig 4) . 14, 46, 47, 49 The lack of males with germline variants in this gene likewise supports the assertion that an intact allele, in at least some tissues of the body, is required for survival. Across all previously and our newly reported associated phenotypes, there are both protein-truncating and missense variants observed, suggesting that the missense variants are likely acting through a loss-of-function mechanism (see Fig 4) . In this study, we identified mosaic SLC35A2 variants from the resected brain tissue of 2 boys with early onset epileptic encephalopathy in the form of intractable epileptic spasms associated with developmental delay. Both had MRI-identified lesions and higher VAFs than the NLFE cases, corresponding to a higher fraction of cells in the brain containing the variant allele; this higher burden of variant SLC35A2 may explain why their presentation more closely resembles the central nervous system features of female cases with germline de novo variants and epileptic encephalopathy. Interestingly, one of the somatic mutation sites identified in this study (c.164G>T;p.Arg55Leu in Case 4) was found to be affected, but with a different amino acid substitution (c.164G>C;p.Arg55Pro), in a fraction of cells in the blood (9% VAF in leukocyte DNA) of a girl with epileptic encephalopathy from a previously published trio sequencing study.
14 This variant was not highlighted in the original report, because mosaic variants at this level in leukocytes had been excluded, 14 but it has since been confirmed to be mosaic and absent in parents (unpublished data). This patient exhibited infantile spasms at age 4 months, developmental delay, and normal MRI, similar to other reported cases with germline SLC35A2 variants. 14, [46] [47] [48] In contrast to the 2 cases with mosaic SLC35A2 variants in brain tissue who presented with epileptic encephalopathy and abnormal MRI, the NLFE cases with mosaic SLC35A2 variants in brain tissue did not present with epileptic encephalopathy or infantile seizure onset. Pathology in these 5 cases showed a range of findings. In the 3 individuals in the NLFE cohort with identified variants in SLC35A2, for whom preoperative MRI did not identify a structural cause responsible for the patients' focal epilepsy, 2 had findings that met criteria for FCD1a, whereas the other had only perielectrode changes (Table 2) . Of the 2 individuals in the MCD cohort found to have variants in SLC35A2, one had only gliosis on pathology and the other gliosis with an excess of neurons in white matter but not sufficient to meet criteria for FCD (Table 2) . Given this range of findings, and the possibility that FCD cannot always be definitively diagnosed by neuropathological assessment because of limited sample size and within-specimen variability, we cannot conclude that a single neuropathological phenotype is associated with mosaic SLC35A2-related dysfunction. Enhanced P-S6 staining was not observed in the resected specimens, and thus the SLC35A2 variants do not appear to be acting through activation of mTOR signaling. We acknowledge, however, that due to sampling constraints and the variability observed across specimens, we cannot definitively say that mTOR-related processes are not contributing to the epileptogenic lesions in these cases.
Consistent with the presence of SLC35A2 variants localized to brain in our 5 cases, we did not observe any systemic signs of a glycosylation defect 48 , and only one case (Case 4), with the highest burden of mosaic SLC35A2, has severe intellectual disability. The bilateral MRI white matter abnormalities seen on MRI of this case may, in retrospect, be consistent with a defect in glycosylation 48 that is more widespread in the brain, but of course we do not have data from other brain regions. Our cases represent a wide range of findings, with presence or absence of MRI lesions, pathological findings suggestive of FCD, and associated intellectual disability. This wide phenotypic range is perhaps not surprising given recent observations in epilepsy genetics. For example, recently a large exome sequencing study of leukocyte DNA from NLFE patients with a family history of epilepsy reported more than expected ultrarare variants in genes previously associated with epileptic encephalopathies in cases compared to controls, suggesting that some of these variants contribute to disease risk. 8 Although SLC35A2 was not specifically implicated in this previously published study, 8 our findings likewise demonstrate that the same gene may underlie phenotypic extremes with the added aspect that variant burden in the brain may also govern aspects of the clinical presentation. In terms of the potential impact of SLC35A2 mosaic variants in nonlesional epilepsy, we found that 16.7% (3/18) of our sequenced NLFE cohort had an SLC35A2 somatic variant identified in brain tissue, allowing us to estimate, based on the calculated 95% confidence interval that somatic variants in SLC35A2 could explain between 3.5 and 42% of cases of NLFE undergoing resection for focal epilepsy. Overall, we demonstrate that SLC35A2 plays a larger role in epilepsy beyond its limited role in a rare subtype of X-linked epileptic encephalopathies.
Somatic mutation has been identified in major structural epileptogenic malformations including hemimegalencephaly, and in FCD type II, which includes dysmorphic neurons in addition to cortical disorganization. [18] [19] [20] 41 However, genes associated with isolated FCD type I, with its subtler cortical disorganization without dysmorphic neurons, have not been previously described, though rare patients with germline genetic syndromes have been described as having FCD type 1 on pathology 50, 51 . Furthermore, the relatively new field of postzygotic mutation in human focal cortical malformation has thus far implicated only genes in the mTOR pathway 18, 20, 41, 52 ; thus, our findings represent a novel, non-mTOR-related genetic cause of somatic mosaic focal epileptic brain lesions. Our findings may consequently have important treatment implications. First, despite growing numbers of cases of FCD type II being explained by somatic variants in the PI3K-AKTmTOR pathway, raising the possibility that mTOR modulation might be a treatment possibility, our data suggest that not all FCD can summarily be classified as uniquely related to this pathway, although a downstream effect on the mTOR pathway cannot be conclusively ruled out. Second, 2 previously reported patients with SLC35A2 variants were reported to have a positive response to treatment with exogenous galactose, 47, 53 raising an interesting possibility for treatment of epilepsy if variants in this gene can be identified early in patients with intractable epilepsy. Collectively, our findings advance our understanding of the pathophysiology of intractable focal epilepsy and the role of somatic mutation in both lesional and nonlesional epilepsy. Furthermore, they present the possibility of innovative, rational therapy for one of the most difficult to treat and common types of epilepsy. 
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